CBS

Chronicles of Biomedical Sciences

journal homepage: https://cbsciences.us/index.php/cbs

Confronting the Looming Threat of Drug-Resistant Tuberculosis

Asif Hanif

King Edward Medical University Lahore Pakistan

ARTICLE INFO

Article Type:
Editorial

Keywords:
Drug Resistant
Tuberculosis
Active case detection
MDR TB

**Corresponding author:*
Asif Hanif
drasif.hanif@hotmail.com

Received on: March 25, 2024.

Revised on: April 20, 2024

Accepted on: April 21, 2024

EDITORIAL

Tuberculosis (TB) remains a global health challenge, and the emergence of drug-resistant strains adds another layer of complexity to this already daunting issue. Drug-resistant tuberculosis, particularly multi-drug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB), poses a grave threat to public health systems worldwide. As we grapple with the ongoing COVID-19 pandemic, it's imperative not to lose sight of the persistent threat of TB, especially its drug-resistant forms. [1]

Firstly, understanding the gravity of the situation is crucial. Drug-resistant TB strains arise due to various factors, including improper treatment regimens, inadequate healthcare infrastructure, and patient non-compliance. MDR-TB and XDR-TB complicate treatment significantly, requiring more prolonged and costly regimens with less guarantee of success. Moreover, these strains can spread more easily, threatening not only individual health but also community well-being. [2]

The consequences of inaction are dire. Unlike drug-sensitive TB, which can often be treated with standard antibiotics, drug-resistant TB demands more extensive and expensive treatments that are not always readily available, especially in resource-constrained settings. This situation leads to poorer treatment outcomes, increased mortality rates, and a higher risk of transmission within communities. Furthermore, the economic burden of managing drug-resistant TB is substantial, straining already stretched healthcare systems and pushing affected individuals deeper into poverty.

Addressing drug-resistant TB requires a multi-faceted approach. Firstly, there must be a concerted effort to strengthen healthcare systems, particularly in regions where TB prevalence is high. This includes improving diagnostic capabilities, ensuring consistent drug supplies, and enhancing healthcare infrastructure to provide comprehensive care to TB patients. Contact screening of drug resistant TB patients is also an important aspect and considered as an effective and cheaper way to foretell the symptomatic active case detection. [3]

Secondly, innovative approaches to TB treatment and prevention are urgently needed. Research into new antibiotics,

vaccines, and diagnostic tools must be prioritized. Additionally, promoting adherence to treatment regimens through patient education and support programs is essential to prevent the development of drug resistance. Drastic efforts have been taken to cope with the issue in Pakistan. [4]

Furthermore, international collaboration is vital in tackling the global spread of drug-resistant TB. TB knows no borders, and concerted efforts are needed to share resources, expertise, and best practices across countries. Initiatives such as the Global Fund to Fight AIDS, Tuberculosis, and Malaria play a crucial role in supporting TB control efforts in low- and middle-income countries. [5]

Lastly, raising awareness about the threat of drug-resistant TB is essential to garnering political will and public support for sustained action. [6] Governments, non-governmental organizations, and the private sector must work together to prioritize TB control efforts and allocate adequate resources to address this pressing public health issue.

In conclusion, drug-resistant tuberculosis is a formidable challenge that requires urgent and sustained action. Failure to address this issue comprehensively risks undoing decades of progress in TB control and jeopardizing the health and well-being of millions worldwide. By prioritizing investment in healthcare systems, fostering innovation in TB treatment and prevention, promoting international collaboration, and raising awareness, we can confront the threat of drug-resistant TB and move closer to achieving the goal of a TB-free world.

References

1. Westhuizen H-M, Ehrlich R, Somdyala N, Greenhalgh T, Tonkin-Crine S, Butler CC. Stigma relating to tuberculosis infection prevention and control implementation in rural health facilities in south africa–a theoretical analysis with opportunities for mitigation. Res Square. 2023;doi: https://doi.org/10.21203/rs.3.rs-3568389/v1.
2. Munir MK, Saeed MS, Haider SZ, Shamim S. Comparison of short term and long term multidrug resistant tuberculosis treatment outcomes in tertiary care settings. Journal of King Saud University-Science. 2024;36:103133.
3. Rehman S, Munir MK, Iqbal R, Salam AA, Saeed S, Masud F, et al. Active case detection among household contacts of multi drug resistant tuberculosis patients in a tertiary care setting. Pak J Med Res. 2014;53(3):55-9.
4. Munir MK, Rehman S, Iqbal R. Meeting the challenge, making a difference: Multidrug resistance tuberculosis in pakistan. Pak J Med Res. 2018;57(1):1-2.
5. Talbot E, Pai M. Tackling drug-resistant tuberculosis: We need a critical synergy of product and process innovations. Int J Tubercu Lung Dis. 2019;23(7):774-82.
6. Iqbal R, Munir M, Rehman S, Saeed S. Treatment strategies in defaulters among mdr tb patients. J Pak Soc Intern Med. 2021;2(1):19-23.